Exploring the Efficacy of Keytruda (Pembrolizumab) in Advancing Treatment Frontiers for NSCLC and Mesothelioma: Insights from Recent Clinical Trials

This article presents updated findings from the phase 1b KEYNOTE-028 study, focusing on the use of Keytruda in small cell lung cancer (SCLC) and malignant pleural mesothelioma.

The study demonstrates promising clinical activity and durable responses in some patients, with an overall response rate (ORR) of 33.3% in SCLC and 20.0% in mesothelioma.

The safety profile of Keytruda remains consistent with previous studies.

Additionally, the article highlights Keytruda's use in PD-L1 positive tumors and its extensive clinical development program encompassing over 30 tumor types.

Updated Findings From KEYNOTE-028 Study

The updated findings from the KEYNOTE-028 study demonstrate clinical activity and durable results in some individuals suffering from malignant pleural mesothelioma and small cell lung cancer (SCLC). The study, which is a phase 1b trial, evaluated the safety and efficacy of Keytruda (pembrolizumab) monotherapy in patients with PD-L1 positive tumors.

The clinical outcomes showed an overall response rate (ORR) of 33.3% in SCLC and 20.0% in mesothelioma. Additionally, the median duration of response was 19.4 months in SCLC and 12.0 months in mesothelioma.

As reported in previous studies, Keytruda had a good safety profile. These findings highlight the potential of Keytruda as a treatment option for patients with SCLC and mesothelioma, particularly those with PD-L1 expression.

Clinical Activity and Durable Responses in Patients

With clinical activity and durable responses observed, Keytruda demonstrates promising potential as a treatment option for patients suffering from malignant pleural mesothelioma and small cell lung cancer.

The updated findings from the phase 1b KEYNOTE-028 study showed a clinical response rate of 33.3% in SCLC and 20.0% in mesothelioma. Additionally, the median duration of response was 19.4 months in SCLC and 12.0 months in mesothelioma.

These clinical outcomes highlight the treatment efficacy of Keytruda in these challenging cancers. Patients receiving Keytruda experienced long-term benefits with durable responses, indicating its therapeutic effectiveness.

These results provide hope for patients who have limited treatment options and emphasize the potential of Keytruda in improving patient outcomes in SCLC and mesothelioma.

Overall Response Rates in SCLC and Mesothelioma

Keytruda demonstrates notable overall response rates against malignant pleural mesothelioma and small cell lung cancer (SCLC). In the phase 1b KEYNOTE-028 study, Keytruda showed an overall response rate (ORR) of 33.3% in SCLC and 20.0% in mesothelioma. These response rates indicate the clinical efficacy of Keytruda in these challenging-to-treat cancers.

Furthermore, the median duration of response was 19.4 months in SCLC and 12.0 months in mesothelioma, suggesting durable treatment outcomes.

Importantly, Keytruda's safety profile in these patients was consistent with previously reported studies, ensuring the well-being of patients undergoing treatment.

These findings highlight the positive patient responses to Keytruda and its potential as a therapeutic option for SCLC and mesothelioma.

Safety Profile Consistent With Previous Studies

The safety profile of Keytruda in patients with malignant pleural mesothelioma and small cell lung cancer (SCLC) is consistent with previously reported studies. Previous safety data has shown that Keytruda has a manageable safety profile. Long term response rates in SCLC and mesothelioma have also been reported, indicating that Keytruda can provide durable responses in some patients.

Additionally, Keytruda has been evaluated in other tumor types as well, further expanding its potential benefits. Keytruda monotherapy has shown promising results in PD-L1 positive tumors, with ongoing studies evaluating its safety and anti-tumor activity. Combination trials with Keytruda and other cancer treatments are also being conducted, aiming to enhance treatment outcomes.

Keytruda in PD-L1 Positive Tumors

Keytruda monotherapy is being tested for safety, tolerability, and anti-tumor activity in more than 450 patients with PD-L1 positive tumors, the ongoing multi-cohort, non-randomized Phase 1b basket trial KEYNOTE-028 aims to assess the overall response rate (ORR) and secondary outcome measures such as progression-free survival (PFS) and overall survival (OS).

The expression of PD-L1 determines the efficacy of Keytruda in these tumors. The trial seeks to determine the extent of anti-tumor activity exhibited by Keytruda in PD-L1 positive tumors, as well as the length of progression-free survival and overall survival. Results from these trials will provide valuable insight into Keytruda's potential as a monotherapy for PD-L1 positive tumors.

Additionally, combination trials involving Keytruda and other cancer treatments are being conducted to explore the synergistic effects and further improve patient outcomes.

Keytruda Clinical Development Program

The extensive clinical development program for Keytruda includes over 30 tumor types and nearly 400 ongoing clinical trials, demonstrating its broad scope and commitment to advancing cancer treatment.

Keytruda is being evaluated in phase 2 trials to assess its progress in treating advanced solid tumors, notably small cell lung cancer (SCLC) or malignant pleural mesothelioma.

Additionally, Keytruda is being studied in combination therapy trials, where it is being combined with other cancer treatments to explore its potential synergistic effects.

The program also includes immuno-oncology research, focusing on developing Keytruda for a range of thoracic malignancies.

The dosing schedule for Keytruda is a fixed dose of 200 mg every three weeks until disease progression or severe toxicity.

Conclusion

In conclusion, the updated findings from the KEYNOTE-028 study demonstrate the clinical activity and durable responses of Keytruda in small cell lung cancer and malignant pleural mesothelioma. Overall response rates and response duration are promising, while the safety profile remains consistent with previous studies.

Keytruda's use in PD-L1 positive tumors is being evaluated in a large number of patients, with various outcome measures.

The results from the KEYNOTE-671 trial also show potential for improving overall survival in resectable NSCLC patients.

Bibliography

"Updated KEYTRUDA® (Pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer - Merck.com." Merck.com, 12 Oct. 2023, (https://www.merck.com/news/updated-keytruda-pembrolizumab-data-in-small-cell-lung-cancer-and-mesothelioma-presented-at-17th-world-conference-on-lung-cancer/)
"Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)." Businesswire.com, 10 Oct. 2023, (https://www.businesswire.com/news/home/20231010865018/en/Merck-Announces-Pivotal-KEYNOTE-671-Trial-Meets-Dual-Primary-Endpoint-of-Overall-Survival-OS-in-Resectable-Stage-II-IIIA-or-IIIB-Non-Small-Cell-Lung-Cancer-NSCLC)
"New Lung Cancer Trial Could Benefit Mesothelioma Patients." Mesothelioma Center - Vital Services for Cancer Patients & Families, 16 Oct. 2020, (https://www.asbestos.com/news/2020/08/19/lung-cancer-trial-ttf-keytruda/)
Pearce, Naomi, and Sian Hope. "Merck Publishes New Data on Keytruda® (Pembrolizumab) in NSCLC and Mesothelioma." Lexology, Pearce IP, 3 June 2023, (https://www.lexology.com/library/detail.aspx?g=e874d0be-a1bc-4106-b79b-889adf0f92d4)
"FDA Approves Keytruda for Certain Mesothelioma Patients." Mesothelioma Center - Vital Services for Cancer Patients & Families, 13 Mar. 2023, (https://www.asbestos.com/news/2020/06/17/fda-approval-keytruda-mesothelioma/)